COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN VERSUS RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION USING REAL-WORLD EVIDENCE IN MEDICARE BENEFICIARIES

被引：0
|
作者：
Peng, S. [1 ]
Deger, K. [1 ]
Ustyugova, A., V [2 ]
Gandhi, P. [3 ]
Qiao, N. [1 ]
Wang, C. [3 ]
Kansal, A. [1 ]
机构：
[1] Evidera, Bethesda, MD USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV61
引用
收藏
页码：A269 / A270
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries
    Peng, Siyang
    Deger, Kristen A.
    Ustyugova, Anastasia
    Gandhi, Pranav
    Qiao, Nan
    Wang, Cheng
    Kansal, Anuraag R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (01) : 55 - 63
  • [2] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [3] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [4] Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
    de Jong, Lisa Aniek
    Gout-Zwart, Judith J.
    van den Bosch, Marina
    Koops, Mike
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 306 - 318
  • [5] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH REAL-WORLD TREATMENT FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN CHINA
    Yang, L.
    Wu, J.
    VALUE IN HEALTH, 2018, 21 : S63 - S63
  • [6] Cost-effectiveness of Apixaban Against Dabigatran and Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Patients
    Lip, Gregory Y.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Liu, Larry Z.
    Lawrence, John
    Dorian, Paul
    CIRCULATION, 2014, 130
  • [7] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    CIRCULATION, 2014, 130
  • [8] Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
    Bengtson, Lindsay G. S.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Alonso, Alvaro
    JOURNAL OF CARDIOLOGY, 2017, 69 (5-6) : 868 - 876
  • [9] Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
    Yang, Lanting
    Brooks, Maria M.
    Glynn, Nancy W.
    Zhang, Yuting
    Saba, Samir
    Hernandez, Inmaculada
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 126 : 29 - 36
  • [10] Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
    Krejczy, Martin
    Harenberg, Job
    Marx, Svetlana
    Obermann, Konrad
    Froelich, Lutz
    Wehling, Martin
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 37 (04) : 507 - 523
12345